Skip To Main Content
Apurvasena Parikh on Muck Rack

Apurvasena Parikh

As seen in: Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Apurvasena

Contact Apurvasena, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Assessment of Telisotuzumab Vedotin Drug-Drug Interaction Potential Using Physiologically‐Based Pharmacokinetic Modeling and Simulations

|
By Patrick Marroum, Apurvasena Parikh, Priya Brunsdon
| Wiley Online Library Verified
Introduction Telisotuzumab vedotin (Teliso-V, ABBV-399) is an antibody-drug conjugate (ADC) comprised of the c-Met targeting antibody telisotuzumab (ABT-700) conjugated to the potent cytotoxic monomethyl auristatin E (MMAE) through a vc-linker. Following intravenous administration, Teliso-V binds to c-Met on the surface of tumor cells, is internalized, and then releases the MMAE payload, leading to microtubule function inhibition, critical cellular process disruption, and cell death.
Open in Who Shared Issue with article?

Optimal Dosing Regimen for Epcoritamab, a Subcutaneous Bispecific Antibody, in Relapsed or Refractory Large B‐Cell Lymphoma

|
By Tommy Li, Leonid Gibiansky, Apurvasena Parikh, Matthew Putnins
| Wiley Online Library Verified
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Epcoritamab, a CD3xCD20 T-cell–engaging bispecific antibody, demonstrated deep and durable responses in patients with relapsed or refractory large B-cell lymphoma (R/R LBCL), including diffuse large B-cell lymphoma, in EPCORE NHL-1 and EPCORE NHL-3. WHAT QUESTION DID THIS STUDY ADDRESS? Is the selected epcoritamab 0.16/0.8/48-mg dosing regimen evaluated in EPCORE NHL-1 and EPCORE NHL-3 appropriate for patients with R/R LBCL?
Open in Who Shared Issue with article?
See all 2 articles